Margreke Brill
PhD candidate / guest
- Name
- Dr. M.J.E. Brill
- Telephone
- +31 71 527 6142
- m.brill@antoniusziekenhuis.nl
PhD candidate / guest
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Blussé van Oud-Alblas H.J., Brill M.J.E., Peeters M.Y.M., Tibboel D., Danhof M. & Knibbe C.A.J. (2019), Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints, BMC Anesthesiology 19: 15.
- Brussee J.M., Yu H., Krekels E.H.J., Palic S., Brill M.J.E., Barrett J.S., Rostami-Hodjegan A., Wildt S.N. de & Knibbe C.A.J. (2018), Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach, Pharmaceutical Research 35: 182.
- Brussee J.M., Yu H., Krekels E.H.J., Roos B. de, Brill M.J.E., Anker J.N. van den, Rostami-Hodjegan A., Wildt S.N. de & Knibbe C.A.J. (2018), First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates, CPT: Pharmacometrics and Systems Pharmacology 7(6): 374-383.
- Brill M.J.E., Välitalo P.A.J., Darwich A.S., Ramshorst B. van, Dongen H.P. van, Rostami-Hodjegan A., Danhof M. & Knibbe C.A. (2016), Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients, CPT: Pharmacometrics and Systems Pharmacology 5(1): 20-30.
- Brill M.J., Rongen A. van, Houwink A.P., Burggraaf J., Ramshorst B. van, Wiezer R.J., Dongen E.P. van & Knibbe C.A. (2014), Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers, Clinical Pharmacokinetics 53(10): 931-941.
- Brill M.J., Houwink A.P., Schmidt S., Dongen E.P. van, Hazebroek E.J., Ramshorst B. van, Deneer V.H., Mouton J.W. & Knibbe C.A.J. (2014), Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis, Journal of Antimicrobial Chemotherapy 69(3): 715-723.
No relevant ancillary activities